# OnCo record fgfr2-fusion-rearrangement (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "fgfr2-fusion-rearrangement" ;
  schema:name "FGFR2 fusion or rearrangement"@en ;
  schema:alternateName "FGFR2 fusion"@en, "FGFR2 rearrangement"@en, "FGFR2-BICC1"@en, "FGFR2::BICC1"@en, "FGFR2 fusion-positive cholangiocarcinoma"@en, "FGFR2 alteration"@en ;
  schema:description "FGFR2 fusions occur in 10 to 15 percent of intrahepatic bile duct cancers and almost nowhere else. Pemigatinib and futibatinib are approved for them after a first chemotherapy."@en ;
  schema:url <https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b1332a1-0581-4707-9bf6-1eccfa39bef4> ;
  onco:tag "biomarker", "fgfr" ;
  onco:related <https://onco.cc/biomarkers/fgfr3-alteration/> ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:drugs <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/futibatinib/>, <https://onco.cc/drugs/infigratinib/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:terms <https://onco.cc/terms/fgfr2-fusion/>, <https://onco.cc/terms/gene-fusion/> .